DNTH
Income statement / Annual
Last year (2024), Dianthus Therapeutics, Inc.'s total revenue was $6.24 M,
an increase of 120.63% from the previous year.
In 2024, Dianthus Therapeutics, Inc.'s net income was -$84.97 M.
See Dianthus Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$6.24 M |
$2.83 M |
$6.42 M |
$1.48 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$355,000.00
|
$147,000.00
|
$2.02 M
|
$1.98 M
|
$1.84 M
|
$875,000.00
|
$376,000.00
|
$6,000.00
|
| Gross Profit |
$6.24 M
|
$2.47 M
|
$6.27 M
|
-$544,000.00
|
-$1.98 M
|
-$1.84 M
|
-$875,000.00
|
-$376,000.00
|
-$6,000.00
|
| Gross Profit Ratio |
1
|
0.87
|
0.98
|
-0.37
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$83.11 M
|
$32.84 M
|
$29.38 M
|
$12.61 M
|
$48.64 M
|
$57.37 M
|
$41.34 M
|
$27.90 M
|
$5.78 M
|
| General & Administrative Expenses |
$24.99 M
|
$18.16 M
|
$6.74 M
|
$1.96 M
|
$28.09 M
|
$23.76 M
|
$18.62 M
|
$7.83 M
|
$3.49 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$875,000.00
|
-$376,000.00
|
-$6,000.00
|
| Selling, General & Administrative Expenses |
$24.99 M
|
$18.16 M
|
$6.74 M
|
$1.96 M
|
$28.09 M
|
$23.76 M
|
$17.75 M
|
$7.45 M
|
$3.48 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$52,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$108.10 M
|
$51.00 M
|
$36.12 M
|
$14.56 M
|
$76.72 M
|
$81.13 M
|
$59.09 M
|
$35.35 M
|
$9.26 M
|
| Cost And Expenses |
$108.10 M
|
$51.00 M
|
$36.12 M
|
$14.56 M
|
$78.70 M
|
$82.97 M
|
$59.96 M
|
$35.73 M
|
$9.27 M
|
| Interest Income |
$17.37 M
|
$4.76 M
|
$1.15 M
|
$3,000.00
|
$3.77 M
|
$0.00
|
$2.45 M
|
$236,000.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$3.56 M
|
$3.77 M
|
$0.00
|
$0.00
|
$0.00
|
$163,000.00
|
| Depreciation & Amortization |
$0.00
|
$355,000.00
|
$147,000.00
|
$2.02 M
|
$1.98 M
|
$1.84 M
|
$875,000.00
|
$376,000.00
|
$6,000.00
|
| EBITDA |
-$101.86 M |
-$48.17 M |
-$29.56 M |
-$13.09 M |
-$72.96 M |
-$74.93 M |
-$56.64 M |
-$35.12 M |
-$9.26 M |
| EBITDA Ratio |
-16.34
|
-17.05
|
-4.63
|
-8.85
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-16.34
|
-17.05
|
-4.63
|
-8.87
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$16.90 M
|
$4.62 M
|
$1.23 M
|
-$23,000.00
|
$3.77 M
|
$6.20 M
|
$2.45 M
|
$236,000.00
|
-$163,000.00
|
| Income Before Tax |
-$84.97 M
|
-$43.56 M
|
-$28.48 M
|
-$13.11 M
|
-$74.94 M
|
-$76.77 M
|
-$57.52 M
|
-$35.49 M
|
-$9.43 M
|
| Income Before Tax Ratio |
-13.63
|
-15.41
|
-4.44
|
-8.88
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.28 M
|
-$2.00 M
|
$7.53 M
|
$6.20 M
|
$2.45 M
|
$236,000.00
|
$0.00
|
| Net Income |
-$84.97 M
|
-$43.56 M
|
-$28.48 M
|
-$13.11 M
|
-$74.94 M
|
-$76.77 M
|
-$57.52 M
|
-$35.49 M
|
-$9.43 M
|
| Net Income Ratio |
-13.63
|
-15.41
|
-4.44
|
-8.88
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.48 |
-8.45 |
-7.6 |
-3.82 |
-27.3 |
-33.18 |
-27.62 |
-16.05 |
-4.27 |
| EPS Diluted |
-2.48 |
-8.45 |
-7.6 |
-3.82 |
-27.3 |
-33.18 |
-27.62 |
-16.05 |
-4.27 |
| Weighted Average Shares Out |
$34.24 M
|
$5.15 M
|
$3.75 M
|
$3.43 M
|
$2.75 M
|
$2.31 M
|
$1.15 M
|
$2.21 M
|
$2.21 M
|
| Weighted Average Shares Out Diluted |
$34.24 M
|
$5.15 M
|
$3.75 M
|
$3.43 M
|
$2.75 M
|
$2.31 M
|
$1.15 M
|
$2.21 M
|
$2.21 M
|
| Link |
|
|
|
|
|
|
|
|
|
